Today: 19 April 2026
Sembcorp Industries share price slips as Alinta vote nears — what SGX investors watch next
26 January 2026
1 min read

Sembcorp Industries share price slips as Alinta vote nears — what SGX investors watch next

Singapore, Jan 26, 2026, 15:38 SGT — Regular session

  • Sembcorp Industries shares dipped slightly on Monday, staying close to the S$6 mark.
  • All eyes are on the shareholder vote set for Jan 30, linked to the Alinta Energy acquisition proposal.
  • Next up: MAS policy review on Jan 29, followed by Sembcorp’s FY2025 results due Feb 25.

Sembcorp Industries Ltd shares dipped 0.3% to S$5.97 on Monday, slipping slightly from Friday’s close of S$5.99. The stock stayed in a narrow range, fluctuating between S$5.97 and S$6.03.

The immediate focus for Sembcorp’s stock remains the upcoming shareholder vote on its proposed acquisition of Australia’s Alinta Energy. That extraordinary general meeting is scheduled for Jan 30.

Addressing shareholder queries, Sembcorp described the acquisition as “earnings- and ROE-accretive.” ROE, or return on equity, gauges how well a company converts shareholders’ equity into profit. The company also noted the deal is expected to generate positive cash flow after covering maintenance capex and debt costs, but cautioned that climate modelling poses uncertainties in assessing risks like extreme weather. Sembcorp

A shareholder circular pegged the enterprise value at A$6.5 billion (around S$5.6 billion) — this figure factors in debt — with the final purchase price set to be adjusted for net debt and working capital at closing. The document also featured a financial fairness opinion from Goldman Sachs (Singapore) on the total consideration.

Macro risks linger quietly in the background. Singapore’s markets are gearing up for the Monetary Authority of Singapore’s policy review on Jan 29. According to a Reuters poll, most economists don’t expect any changes. Since MAS manages policy via the exchange rate instead of a benchmark interest rate, any unexpected move could still affect funding costs and shake sentiment around rate-sensitive sectors like utilities.

Sembcorp is set to unveil its FY2025 financial results on Feb 25, ahead of the market open. A webcast briefing will follow at 11 a.m. Singapore time. Investors will be watching closely for updates on cash flow and dividend guidance as the company approaches the Alinta vote.

Yet the trade runs both ways. A clean vote and a straightforward closing would shift attention to integration and execution; resistance on leverage, terms, or timing could keep the stock stuck.

Investors are keeping an eye on the usual deal mechanics — things like completion adjustments, regulatory hurdles, and currency fluctuations — since these factors can alter the headline price even after the vote.

The Jan 30 shareholder meeting is the immediate trigger. Then, all eyes shift to Feb 25, when results drop and any updated guidance will give investors a clearer idea if the new Australia footprint boosts returns or just creates more uncertainty.

Stock Market Today

  • Brown-Forman (BF.B) Faces Valuation Debate After Strong Short-Term Rally
    April 18, 2026, 9:26 PM EDT. Brown-Forman's (BF.B) stock surged about 27% in one month, reversing last year's roughly 11% decline. The recent sharp rebound contrasts with a weaker long-term trend, highlighting momentum shifts. Despite shares trading near analyst price targets at $29.15, fair value estimates diverge widely. Simply Wall St's discounted cash flow (DCF) model values Brown-Forman at $37.78, suggesting undervaluation, while another model pegs fair value at $21.00, indicating the stock is roughly 39% overvalued. The gap reflects differing views on declining global alcohol consumption due to rising health awareness, which could pressure Brown-Forman's revenue growth. However, premium spirits and emerging market demand might offset some risks. Investors face critical decisions amid mixed signals, weighing whether current prices embed growth prospects or overestimate future earnings.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Netflix to Paramount: Your Warner Bros bid “doesn’t pass the sniff test” as takeover clock ticks
Previous Story

Netflix to Paramount: Your Warner Bros bid “doesn’t pass the sniff test” as takeover clock ticks

Shell share price: RBC downgrade puts SHEL.L in focus ahead of Feb 5 results
Next Story

Shell share price: RBC downgrade puts SHEL.L in focus ahead of Feb 5 results

Go toTop